ASCO 2016 State of Cancer Report Delivers Strong Warnings for the Future of Oncology Care
This week in healthcare: ASCO State of Cancer report highlights major challenges for patients and physicians, including uneven health insurance coverage, rapidly rising costs, and other barriers to accessing new treatments.
U.S. Cancer Care System Ill-Equipped to Deliver New Advances to Patients, ASCO Report Finds
In their annual State of Cancer Care in America report, ASCO argues that “As the nation embarks on an ambitious “moonshot” to accelerate progress against cancer, our system for delivering today’s cancer treatments must be better prepared to bring advances to all patients.”
Recently the Journal of Clinical Pathways announced a group of five individuals who will comprise the steering committee for their upcoming first-ever Clinical Pathways Congress.
Flatiron Health and Via Oncology Announce Availability of Via Pathways for Medical Oncology in OncoEMR(R)
Recently Flatiron Health and Via Oncology announced that “Via Pathways for breast, colon, rectal, non-small cell and small-cell lung, mesothelioma, prostate, and multiple myeloma cancers are now available fully embedded in Flatiron Health’s OncoEMR electronic health record (EHR).”
Anthem Price Dispute Continues to Loom over Express Scripts
On a recent Express Scripts conference call, the tension was apparent in a continued dispute between Express Scripts and Anthem, who says they are “entitled to new pricing terms effective Dec. 1, 2015”.
This ASCO report takes a look at the construction of the White House’s cancer moonshot initiative so far, including the ways that some of ASCO’s experts have been able to contribute.
In this short video, Patrick Soon-Shiong discusses the cancer moonshot and how it aims to completely change the way we approach and treat cancer.
A recent report suggests that “if all CML (chronic myeloid leukemia) patients were started upon diagnosis on the generic form of Gleevec, known as imatinib, the cost of treatment per patient over five years would be nearly $100,000 less than it is now.”
Black and Blues: Plans Expected to Boost Rates, Narrow Networks
Reports are suggesting and Blues plans will be raising rates and narrowing networks after a rough year: “Full-year 2015 earnings among Blues plans are expected to show a deep decline after 23 of 35 Blues plan collectively reported an earnings drop of $1.9 billion for the first nine months of the year, largely due to their experiences on public exchanges.”
Employers Add Tiers, Tighten Specialty Drug Controls in 2017 Pharmacy Benefits
Experts suggest that as drug prices remain high, employers are finding ways to try to take control and they “are more and more emboldened in their use of rigid controls by the increasing commonality of tiered formularies and outright exclusions.”
Vice President Joe Biden has announced Greg Simon as the executive director of the White House’s moonshot cancer cure initiative. Mr. Simon is a former senior vice president at Pfizer and a former Al Gore advisor, as well as a recent cancer patient himself.
Recently Horizon Pharma disclosed the compensation package for their CEO, Timothy Walbert, in 2015. The total? A whopping $93 million.
This article takes a look at some of the proposed Medicare reimbursement reform strategies set forth in CMS’s new value-based pricing proposal.
Want more health care landscape updates and insights? Follow us on Twitter @innovpartners.